Skip to main content
Top
Published in: Respiratory Research 1/2012

Open Access 01-12-2012 | Research

Comparison of the variability of the annual rates of change in FEV1 determined from serial measurements of the pre- versus post-bronchodilator FEV1 over 5 years in mild to moderate COPD: Results of the lung health study

Authors: Donald P Tashkin, He-Jing Wang, David Halpin, Eric C Kleerup, John Connett, Ning Li, Robert Elashoff

Published in: Respiratory Research | Issue 1/2012

Login to get access

Abstract

Background

The impact of interventions on the progressive course of COPD is currently assessed by the slope of the annual decline in FEV1 determined from serial measurements of the post-, in preference to the pre-, bronchodilator FEV1. We therefore compared the yearly slope and the variability of the slope of the pre- versus the post-bronchodilator FEV1 in men and women with mild to moderate COPD who participated in the 5-year Lung Health Study (LHS).

Methods

Data were analyzed from 4484 of the 5887 LHS participants who had measurements of pre- and post-bronchodilator FEV1 at baseline (screening visit 2) and all five annual visits. The annual rate of decline in FEV1 (±SE) measured pre- and post-bronchodilator from the first to the fifth annual visit was estimated separately using a random coefficient model adjusted for relevant covariates. Analyses were performed separately within each of the three randomized intervention groups. In addition, individual rates of decline in pre- and post-bronchodilator FEV1 were also determined for each participant. Furthermore, sample sizes were estimated for determining the significance of differences in slopes of decline between different interventions using pre- versus post-bronchodilator measurements.

Results

Within each intervention group, mean adjusted and unadjusted slope estimates were slightly higher for the pre- than the post-bronchodilator FEV1 (range of differences 2.6-5.2 ml/yr) and the standard errors around these estimates were only minimally higher for the pre- versus the post-bronchodilator FEV1 (range 0.05-0.11 ml/yr). Conversely, the standard deviations of the mean FEV1 determined at each annual visit were consistently slightly higher (range of differences 0.011 to 0.035 L) for the post- compared to the pre-bronchodilator FEV1. Within each group, the proportion of individual participants with a statistically significant slope was similar (varying by only 1.4 to 2.7%) comparing the estimates from the pre- versus the post-bronchodilator FEV1. However, sample size estimates were slightly higher when the pre- compared to the post-bronchodilator value was used to determine the significance of specified differences in slopes between interventions.

Conclusion

Serial measurements of the pre-bronchodilator FEV1 are generally sufficient for comparing the impact of different interventions on the annual rate of change in FEV1.
Appendix
Available only for authorised users
Literature
3.
go back to reference Casanova C, de Torres JP, Aguirre-Jaime A, Pinto-Plata V, Marin JM, Cordoba E, BAz R, kKCote C, Celli BR: The progression of chronic obstructive pulmonary disease is heterogeneous. The experience of the BODE cohort. Am J Respir Crit Care Med. 2011, 184: 1015-1021. 10.1164/rccm.201105-0831OC.PubMedCrossRef Casanova C, de Torres JP, Aguirre-Jaime A, Pinto-Plata V, Marin JM, Cordoba E, BAz R, kKCote C, Celli BR: The progression of chronic obstructive pulmonary disease is heterogeneous. The experience of the BODE cohort. Am J Respir Crit Care Med. 2011, 184: 1015-1021. 10.1164/rccm.201105-0831OC.PubMedCrossRef
4.
go back to reference Detels R, Tashkin DP, Sayre JW, Rokaw SN, Massey FJ, Coulson AH, Wegman DH: The UCLA population studies of CORD. X. A cohort study of changes in respiratory function associated with chronic exposure to SOX, NOX and hydrocarbons. Am J Public Health. 1991, 81: 350-359. 10.2105/AJPH.81.3.350.PubMedPubMedCentralCrossRef Detels R, Tashkin DP, Sayre JW, Rokaw SN, Massey FJ, Coulson AH, Wegman DH: The UCLA population studies of CORD. X. A cohort study of changes in respiratory function associated with chronic exposure to SOX, NOX and hydrocarbons. Am J Public Health. 1991, 81: 350-359. 10.2105/AJPH.81.3.350.PubMedPubMedCentralCrossRef
5.
go back to reference Tashkin DP, Detels R, Simmons M, Liu H, Coulson AH, Sayre J, Rokaw S: The UCLA Population Studies of Chronic Obstructive Respiratory Disease XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med. 1994, 149: 1209-1217.PubMedCrossRef Tashkin DP, Detels R, Simmons M, Liu H, Coulson AH, Sayre J, Rokaw S: The UCLA Population Studies of Chronic Obstructive Respiratory Disease XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med. 1994, 149: 1209-1217.PubMedCrossRef
6.
go back to reference Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB: The natural history of chronic airflow obstruction revised. An analysis of the Framingham Offsping Cohort. Am J Respir Crit Care Med. 2009, 180: 3-10. 10.1164/rccm.200901-0047OC.PubMedCrossRef Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB: The natural history of chronic airflow obstruction revised. An analysis of the Framingham Offsping Cohort. Am J Respir Crit Care Med. 2009, 180: 3-10. 10.1164/rccm.200901-0047OC.PubMedCrossRef
7.
go back to reference Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O’Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA, for the Lung Health Study Research Group, for the Lung Health Study Research Group: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994, 272: 1497-1505. 10.1001/jama.1994.03520190043033.PubMedCrossRef Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O’Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA, for the Lung Health Study Research Group, for the Lung Health Study Research Group: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994, 272: 1497-1505. 10.1001/jama.1994.03520190043033.PubMedCrossRef
8.
go back to reference Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP, for the Lung Health Study Research Group, for the Lung Health Study Research Group: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the lung health study. Am J Respir Crit Care Med. 2000, 161: 381-390.PubMedCrossRef Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP, for the Lung Health Study Research Group, for the Lung Health Study Research Group: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the lung health study. Am J Respir Crit Care Med. 2000, 161: 381-390.PubMedCrossRef
9.
go back to reference Pauwels RA, Lofdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Eng J Med. 1999, 340: 1948-1953. 10.1056/NEJM199906243402503.CrossRef Pauwels RA, Lofdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Eng J Med. 1999, 340: 1948-1953. 10.1056/NEJM199906243402503.CrossRef
10.
go back to reference Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000, 320: 1297-1303. 10.1136/bmj.320.7245.1297.PubMedPubMedCentralCrossRef Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000, 320: 1297-1303. 10.1136/bmj.320.7245.1297.PubMedPubMedCentralCrossRef
11.
go back to reference Vesto J, Sorensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide im mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 1999, 353: 1819-1823. 10.1016/S0140-6736(98)10019-3.CrossRef Vesto J, Sorensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide im mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 1999, 353: 1819-1823. 10.1016/S0140-6736(98)10019-3.CrossRef
12.
go back to reference The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000, 343: 1902-1909.CrossRef The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000, 343: 1902-1909.CrossRef
13.
go back to reference Decramer M, Rutten-van Molken M, Dekhuijzen PNR, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CPO, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005, 365: 1552-1560. 10.1016/S0140-6736(05)66456-2.PubMedCrossRef Decramer M, Rutten-van Molken M, Dekhuijzen PNR, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CPO, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005, 365: 1552-1560. 10.1016/S0140-6736(05)66456-2.PubMedCrossRef
14.
go back to reference Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, for the UPLIFT study investigators, for the UPLIFT study investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 1543-1554. 10.1056/NEJMoa0805800.PubMedCrossRef Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, for the UPLIFT study investigators, for the UPLIFT study investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 1543-1554. 10.1056/NEJMoa0805800.PubMedCrossRef
15.
go back to reference Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA: Effect of pharmacotherapy on rate of decline in lung function in chronic obstructive pulmonary disease. Results from the TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-338. 10.1164/rccm.200712-1869OC.PubMedCrossRef Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA: Effect of pharmacotherapy on rate of decline in lung function in chronic obstructive pulmonary disease. Results from the TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-338. 10.1164/rccm.200712-1869OC.PubMedCrossRef
16.
go back to reference Postma DS, Hoeter GH, vd Mark TW, Reig RP, Sluiter HJ: The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest. 1985, 87: 653-657. 10.1378/chest.87.5.653.PubMedCrossRef Postma DS, Hoeter GH, vd Mark TW, Reig RP, Sluiter HJ: The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest. 1985, 87: 653-657. 10.1378/chest.87.5.653.PubMedCrossRef
17.
go back to reference Pennock BE, Rogers RM, McCaffree DR: Changes in measured spirometric indices. What is significant?. Chest. 1981, 80: 97-99. 10.1378/chest.80.1.97.PubMedCrossRef Pennock BE, Rogers RM, McCaffree DR: Changes in measured spirometric indices. What is significant?. Chest. 1981, 80: 97-99. 10.1378/chest.80.1.97.PubMedCrossRef
18.
go back to reference Nisar M, Earis JE, Pearson MG, Calverley PMA: Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991, 146: 555-559.CrossRef Nisar M, Earis JE, Pearson MG, Calverley PMA: Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991, 146: 555-559.CrossRef
19.
go back to reference Enright PL, Johnson LR, Connett JE, voelker H, Buist AS: Spirometry in the Lung Health Study: I. Methods and quality control. Am Rev Respir Dis. 1991, 143: 1215-1233.PubMedCrossRef Enright PL, Johnson LR, Connett JE, voelker H, Buist AS: Spirometry in the Lung Health Study: I. Methods and quality control. Am Rev Respir Dis. 1991, 143: 1215-1233.PubMedCrossRef
20.
go back to reference Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R, for the Lung Health Study Research Group, for the Lung Health Study Research Group: The Lung Health Study: Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis. 1992, 145: 301-310.PubMedCrossRef Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R, for the Lung Health Study Research Group, for the Lung Health Study Research Group: The Lung Health Study: Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis. 1992, 145: 301-310.PubMedCrossRef
21.
go back to reference Crapo RD, Morris AH, Gardner RM: Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981, 123: 659-664.PubMed Crapo RD, Morris AH, Gardner RM: Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981, 123: 659-664.PubMed
22.
go back to reference O’Connor GT, Sparrow D, Weiss ST: A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary function decline: the Normative Aging Study. Am J Respir Crit Care Med. 1995, 152: 87-92.PubMedCrossRef O’Connor GT, Sparrow D, Weiss ST: A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary function decline: the Normative Aging Study. Am J Respir Crit Care Med. 1995, 152: 87-92.PubMedCrossRef
23.
go back to reference Calverley PMA, Lee A, Towse L, van Noord J, Witeck TJ, Kelsen S: Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003, 58: 855-860. 10.1136/thorax.58.10.855.PubMedPubMedCentralCrossRef Calverley PMA, Lee A, Towse L, van Noord J, Witeck TJ, Kelsen S: Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003, 58: 855-860. 10.1136/thorax.58.10.855.PubMedPubMedCentralCrossRef
24.
go back to reference van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Meuller A, Cornelissen PJG: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006, 129: 509-517. 10.1378/chest.129.3.509.PubMedCrossRef van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Meuller A, Cornelissen PJG: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006, 129: 509-517. 10.1378/chest.129.3.509.PubMedCrossRef
25.
go back to reference Tashkin DP: Measurement and Significance of the Bronchodilator Response. Bronchodilators: Theory and Practice. Edited by: Jenne JW. 1987, Marcel Dekker, Inc, New York, 535-613. Tashkin DP: Measurement and Significance of the Bronchodilator Response. Bronchodilators: Theory and Practice. Edited by: Jenne JW. 1987, Marcel Dekker, Inc, New York, 535-613.
26.
go back to reference Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW, for the ISOLDE Study Investigators, for the ISOLDE Study Investigators: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003, 58: 659-664. 10.1136/thorax.58.8.659.PubMedPubMedCentralCrossRef Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW, for the ISOLDE Study Investigators, for the ISOLDE Study Investigators: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003, 58: 659-664. 10.1136/thorax.58.8.659.PubMedPubMedCentralCrossRef
27.
go back to reference Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ: The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999, 115: 966-971. 10.1378/chest.115.4.966.PubMedCrossRef Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ: The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999, 115: 966-971. 10.1378/chest.115.4.966.PubMedCrossRef
28.
go back to reference Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S: Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008, 31: 742-750. 10.1183/09031936.00129607.PubMedCrossRef Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S: Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008, 31: 742-750. 10.1183/09031936.00129607.PubMedCrossRef
29.
go back to reference Celli B, Tashkin DP, Rennard SI, McElhattan J, Martin U: Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in patients with COPD. Respir Med. 2011, 105: 1176-1188. 10.1016/j.rmed.2011.02.020.PubMedCrossRef Celli B, Tashkin DP, Rennard SI, McElhattan J, Martin U: Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in patients with COPD. Respir Med. 2011, 105: 1176-1188. 10.1016/j.rmed.2011.02.020.PubMedCrossRef
30.
go back to reference Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE: Bronchodilator response in mild to moderate COPD over 11 years: Results from the Lung Health Study. Eur Respir J. 2005, 26: 45-51. 10.1183/09031936.05.00102604.PubMedCrossRef Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE: Bronchodilator response in mild to moderate COPD over 11 years: Results from the Lung Health Study. Eur Respir J. 2005, 26: 45-51. 10.1183/09031936.05.00102604.PubMedCrossRef
31.
go back to reference DuBois AB: Resistance to breathing. Handbook of Physiology, Section 3: Respiration, vol 1. Edited by: Fenn WO, Rahn H. 1964, American Physiological Society, Washington, DC, 451-452. DuBois AB: Resistance to breathing. Handbook of Physiology, Section 3: Respiration, vol 1. Edited by: Fenn WO, Rahn H. 1964, American Physiological Society, Washington, DC, 451-452.
32.
go back to reference Mannino DM, Diaz-Guzman E, Buist S: Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respir Res. 2011 Oct 12, 12: 136-10.1186/1465-9921-12-136.PubMedPubMedCentralCrossRef Mannino DM, Diaz-Guzman E, Buist S: Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respir Res. 2011 Oct 12, 12: 136-10.1186/1465-9921-12-136.PubMedPubMedCentralCrossRef
Metadata
Title
Comparison of the variability of the annual rates of change in FEV1 determined from serial measurements of the pre- versus post-bronchodilator FEV1 over 5 years in mild to moderate COPD: Results of the lung health study
Authors
Donald P Tashkin
He-Jing Wang
David Halpin
Eric C Kleerup
John Connett
Ning Li
Robert Elashoff
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2012
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-13-70

Other articles of this Issue 1/2012

Respiratory Research 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine